Who are Panzytrat 25.000 FIP-E units of Lipase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pancrelipase Capsules, Pancreatic Enzyme, creon 35.000 Ph.U (R), Creon N, Creon® 10000, PANCRECARB® (pancrelipase).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/panzytrat-25-000-fip-e-units-of-lipase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Panzytrat 25.000 FIP-E units of Lipase — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Panzytrat 25.000 FIP-E units of Lipase (Panzytrat 25.000 FIP-E units of Lipase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pancreatic enzyme replacement therapy. Area: Gastroenterology.

marketed Pancreatic enzyme replacement therapy Triglycerides and dietary lipids Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Panzytrat 25.000 FIP-E units of Lipase (Panzytrat 25.000 FIP-E units of Lipase) — Foundation for Liver Research. Panzytrat is a pancreatic enzyme replacement therapy containing lipase that aids in the digestion and absorption of dietary fats.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Panzytrat 25.000 FIP-E units of Lipase TARGET	Panzytrat 25.000 FIP-E units of Lipase	Foundation for Liver Research	marketed	Pancreatic enzyme replacement therapy	Triglycerides and dietary lipids
Pancrelipase Capsules	Pancrelipase Capsules	Ohio State University	marketed	Pancreatic enzyme replacement therapy
Pancreatic Enzyme	Pancreatic Enzyme	University of Oxford	marketed	Pancreatic enzyme replacement therapy (PERT)
creon 35.000 Ph.U (R)	creon 35.000 Ph.U (R)	Hospital Clinico Universitario de Santiago	marketed	Pancreatic enzyme replacement therapy
Creon N	Creon N	Abbott	phase 3	Pancreatic enzyme replacement therapy
Creon® 10000	Creon® 10000	Abbott	phase 3	Pancreatic enzyme replacement therapy
PANCRECARB® (pancrelipase)	PANCRECARB® (pancrelipase)	Digestive Care, Inc.	phase 3	Pancreatic enzyme replacement therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pancreatic enzyme replacement therapy class)

Abbott · 2 drugs in this class
Asian Institute of Gastroenterology, India · 1 drug in this class
Digestive Care, Inc. · 1 drug in this class
Foundation for Liver Research · 1 drug in this class
Hospital Clinico Universitario de Santiago · 1 drug in this class
Ohio State University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Panzytrat 25.000 FIP-E units of Lipase — Competitive Intelligence Brief. https://druglandscape.com/ci/panzytrat-25-000-fip-e-units-of-lipase. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab